CAESAREA, Israel March 12, 2009 - Allium Group, the developer and manufacturer of innovative stents for the urinary, gastro-intestinal, pulmonary and peripheral vascular tracts, announced today the nomination of the former Director General of Hadassah Medical Organization, Prof. Shmuel Penchas, as a member of the Board of Directors. Prof. Penchas' first-time decision to join the board of a stent company reflects his confidence in Allium medical stents’ contribution to providing a life-enhancing solution for patients.
A pioneer in the stenting industry, Allium Medical is the first company to develop and manufacture removable next-generation stents geared towards offering minimally invasive treatments for malignant and benign obstructions in the urinary, and gastro-intestinal tract. An advocate of generating awareness of this minimally invasive method, Prof. Penchas role on the board of directors will involve strategic positioning and use of his ample experience and global medical contacts to open up greater opportunities for the company internationally.
“In today’s age of technology, the expanding multi-billion dollar stenting industry is growing as healthcare professionals and hospitals gain greater accessibility to this minimally invasive alternative,” said Prof. Penchas. "Having developed the sole next-generation removable medical stents, Allium Medical is revolutionizing procedures and steering many medical fields into a new direction."
For eighteen years, Prof. Penchas ran Hadassah’s state-of-the-art hospitals as Director General of the Hadassah Medical Organization. A committed and well regarded contributor to the medical industry, Prof. Penchas has spearheaded numerous healthcare projects. Member of the Institute of Medicine and National Academy of Sciences in the United States, Prof. Penchas is a frequent contributor and positioned expert in global healthcare, having published literature on complexity in healthcare systems.
Limor Domnitz Gishri, Allium’s CEO, commented, ”Allium Medical is delighted about the board appointment of such a veteran in the medical field. Prof. Shmuel Penchas not only provides the medical seal of approval for our pioneering stent technology, but we will greatly benefit from his stewardship and deep knowledge of medical challenges in providing effective treatment to patients.”
The recent launch of three CE mark awarded stents have diversified Allium medical's global offering, extending its current portfolio of stents to include prostate, bladder-neck and bulbar urethral stents. Allium's biliary and ureteral stents are currently being distributed through numerous partners in various European markets including Italy, United Kingdom, Germany and Austria, Benelux, Spain, Greece, Scandinavia and South Africa.
About Allium Medical
Founded in 2001, Allium Medical is a privately owned medical device company offering next-generation stents based on a proprietary technological platform that enables physicians to offer more effective stent solutions for enhancing patients' quality of life. Allium Medical has developed site-specific, anatomically and functionally compatible stents with applications in the urinary and gastro-intestinal tracts. Allium was awarded CE marks for its biliary and ureteral stents, commencing sales in Europe in June 2007 and receiving follow-up orders from its distributors thereafter. Distribution of Allium's new prostatic stent which also recently received a CE Certification, and the posterior urethral /bladder-neck stents will begin during the first months of 2009. Allium’s headquarters, R&D and manufacturing facilities are located in Caesarea, Israel.